



**Figure S1. CD138<sup>+</sup> and CD138<sup>-</sup> cells were purified using Human CD138 MicroBeads from BMMCs of MM patients. Representative dot plots of flow cytometry analyses of CD138<sup>+</sup> and CD138<sup>-</sup> purity.**

**Figure S1**



**Figure S2. DCZ3301 induced G<sub>2</sub>/M phase arrest in MM cell RPMI-8266, but not non-MM cells MOLT-4, 786-0, or LM3. RPMI-8266, MOLT-4, 786-0 and LM3 cells were treated with indicated concentrations of DCZ3301 for 24h. Cell cycle was analyzed by flow cytometry using PI staining. Bar graph shows percentage of cell populations in G1, S or G<sub>2</sub>/M phase of cell cycle.**

**Figure S2**



**Figure S3. DCZ3301 had no effect on ERK1/2, p65, AKT, or STAT3 phosphorylation in normal and IgM-stimulated B cells.** B lymphocytes from freshly isolated PBMCs were stimulated for 24h with a F(ab')<sub>2</sub> goat anti-human IgM at a final concentration of 10 µg/mL. Cells were then treated with 8µM DCZ3301 for 24h, lysed, and subjected to western blotting for p-ERK1/2, p-p65, p-AKT, p-STAT3 and β-actin.

